Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy
Not Applicable
Completed
- Conditions
- Mitochondrial Myopathy
- Registration Number
- NCT00004770
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Brief Summary
OBJECTIVES:
I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial myopathy.
- Detailed Description
PROTOCOL OUTLINE: The patient receives one thioctic acid tablet 3 times a day. If patient experiences no side effects after 1 week, 2 tablets are administered and given 3 times a day over 3 months for compassionate use.
The patient is followed at weeks 3, 8, and 12.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie thioctic acid's efficacy in mitochondrial myopathy as studied in NCT00004770?
How does thioctic acid compare to standard antioxidants like CoQ10 in mitochondrial myopathy treatment?
Which biomarkers predict response to thioctic acid in mitochondrial myopathy patients?
What are the long-term adverse events of thioctic acid in mitochondrial myopathy treatment?
Are there combination therapies with thioctic acid and creatine for mitochondrial disease management?